Professor Paul Timpson
Professor Paul Timpson completed his PhD with Professor Margaret Frame at the Beatson Institute for Cancer Research, UK in 2002 where he assessed the interplay between Src family kinases and the actin cytoskeleton during cancer cell invasion, focusing on the role of Rho family GTPases. He then moved to the Garvan Institute of Medical Research in 2003 to work with Professor Roger Daly investigating the role of the actin-binding protein cortactin in growth factor receptor trafficking in breast cancer and head and neck cancers. Paul was awarded an AstraZeneca Postdoctoral Research Fellowship allowing him to return to the Beatson Institute in 2007, to work with Professor Kurt Anderson in collaboration with AstraZeneca Advanced Technology Laboratories. This ongoing work has focused upon the development of novel multi-disciplinary live imaging techniques to investigate molecular dynamics of cancer cells in vivo. Having returned to Australia to establish a research group in November 2012 within the Cancer Program, Paul aims to understand disease in the context of the surrounding environment using cutting edge in vitro and in vivo imaging technology. Pinpointing the molecular drivers of cancer progression and the environmental cues that cause resistance to current systemic therapy are the focus of his research.
- 1998GlaxoWellcome - University (Hons) award - Pharmacology - UK
- 2001Beatson Institute PhD Career Development award - Glasgow - UK
- 2001Cancer Research Campaign - PhD Award - London - UK
- 2004AMGEN Postdoctoral Early Career Research prize - Australia
- 2007AstraZeneca Research Fellowship - UK
- 2010Actin Prize - Bristol - UK
- 2010Cancer Research UK - CRUK posdoctoral Research Award - UK
- 2011European Association for Cancer Research Award (EACR) Australia
- 2012Australian Research Council (ARC) Future Fellowship - Australia
- 2013CINSW Fellowship - NSW - Sydney - Australia
- 2018NHMRC Senior Research Fellowship - Australia
- 2023NHMRC Investigator Grant - Australia
- 2023Science advances10.1126/sciadv.adf9063
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse.
- 2021Science advances10.1126/sciadv.abh0363
Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status.
- 2019Nature communications10.1038/s41467-019-10968-6
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.
- 2017Science translational medicine10.1126/scitranslmed.aai8504
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Removing physiological motion from intravital and clinical functional imaging data.